ALRN - Aileron Therapeutics Inc Stock Price, Fair Value and News

$2.07-0.10 (-4.61%)

Delayed as of 26 Dec 2024, 12:15 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ALRN Price Action

Last 7 days

13.0%

Last 30 days

-12.1%

Last 90 days

-32.4%

Trailing 12 Months

-31.1%

ALRN RSI Chart

ALRN Valuation

Market Cap

47.0M

Price/Earnings (Trailing)

-1.61

Price/Sales (Trailing)

323.04

Price/Free Cashflow

-1.69

ALRN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ALRN Fundamentals

ALRN Revenue

Revenue (TTM)

222.0K

ALRN Earnings

Earnings (TTM)

-29.2M

Earnings Growth (Yr)

-220.03%

Earnings Growth (Qtr)

34.61%

ALRN Profitability

Return on Equity

-424.58%

Return on Assets

-28.06%

Free Cashflow Yield

-59.28%

ALRN Investor Care

Shares Dilution (1Y)

377.10%

Diluted EPS (TTM)

-3.15

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	0	0	222.0K	0
2016	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

CEO	Dr. Manuel C. Aivado M.D., Ph.D.
WEBSITE	aileronrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	6

Aileron Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aileron Therapeutics Inc? What does ALRN stand for in stocks?

ALRN is the stock ticker symbol of Aileron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aileron Therapeutics Inc (ALRN)?

As of Tue Dec 24 2024, market cap of Aileron Therapeutics Inc is 47.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALRN stock?

You can check ALRN's fair value in chart for subscribers.

Is Aileron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALRN is over valued or under valued. Whether Aileron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aileron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALRN.

What is Aileron Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, ALRN's PE ratio (Price to Earnings) is -1.61 and Price to Sales (PS) ratio is 323.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALRN PE ratio will change depending on the future growth rate expectations of investors.